Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K; COR-Diabetes Study Group. Hollander P, et al. Diabetes Care. 2013 Dec;36(12):4022-9. doi: 10.2337/dc13-0234. Epub 2013 Oct 21. Diabetes Care. 2013. PMID: 24144653 Free PMC article. Clinical Trial.
Acarbose in the treatment of type I diabetes.
Hollander P, Pi-Sunyer X, Coniff RF. Hollander P, et al. Diabetes Care. 1997 Mar;20(3):248-53. doi: 10.2337/diacare.20.3.248. Diabetes Care. 1997. PMID: 9051366 Clinical Trial.
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohórquez SM, Eng W, Långström B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB. Erondu N, et al. Among authors: hollander p. Cell Metab. 2006 Oct;4(4):275-82. doi: 10.1016/j.cmet.2006.08.002. Cell Metab. 2006. PMID: 17011500 Free article. Clinical Trial.
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.
Rosenstock J, Hollander P, Chevalier S, Iranmanesh A; SERENADE Study Group. Rosenstock J, et al. Among authors: hollander p. Diabetes Care. 2008 Nov;31(11):2169-76. doi: 10.2337/dc08-0386. Epub 2008 Aug 4. Diabetes Care. 2008. PMID: 18678611 Free PMC article. Clinical Trial.
254 results